Happy Fall, MedscapeLIVE! Dermatology readers! A lot is happening in dermatology, and the 2025 Las Vegas Dermatology is the perfect meeting to get brought up to speed. From September 11 through 13, faculty from all over the nation and will cover topics all over the clinical dermatology spectrum— including atopic dermatitis, psoriasis, acne, rosacea, and more. For the third and final day of the meeting, Medscape will present a brand new Cutaneous Malignancies Forum—a full day dedicated to best-practice management of various cutaneous malignancies. If you can’t attend, check out the upcoming Skin of Color Update, which is from October 3-5 in NYC. You can register here.

‍

This month catch up with the 4 co-chairs of LVD, Dr. Tina Bhutani, Dr. Lawrence F. Eichenfield, Dr. Vishal A. Patel, and Dr. Adam Friedman, who candidly share their thoughts and opinions on all things new in treatment options and with LVD. Read on to see what they say when the microphone is off!

‍

Thank you to these thought leaders for sharing their perspectives. Please contact me at colleen@cmhadvisors.com with comments or suggestions, and thanks for reading!—Colleen Hutchinson

‍

Five Minutes with Drs. Tina Bhutani, Lawrence F. Eichenfield, Adam Friedman, and Vishal A. Patel

Bios for Drs. Bhutani, Eichenfield, Friedman, and Patel can be found here.

‍

Dr. Adam Friedman

What are some buzzwords that will come up in your talk Cutaneous Fungal Infections? One of the first things you will hear “if it scales, you better scrape it!” as other buzz words like antifungal resistance stem from the injudicious use of antifungals for clinical mimickers. These infections are evolving beyond “bread and butter derm;” We’re dealing with emerging resistance patterns requiring unique application of evolving diagnostics and treatment paradigms. “Stewardship” is key, both in how we prescribe antifungals and how we ensure dermatophytoses are included in our  differential diagnosis, especially the dreaded tinea incognito (another buzzword!)

‍

What will attendees gain from your ZORYVE presentation? The ZORYVE session will highlight not just what the drug is, but how it can change the way we practice and address historical gaps. I want attendees to walk away with a deeper understanding of the PDE4/cAMP axis, how topical innovation is finally catching up to systemic science, and most importantly, the real world impact for patients across multiple disease states. It’s about bridging mechanism and purposeful vehicle design with meaningful outcomes, and giving clinicians the confidence and tools to integrate it effectively into practice.

‍

You intro and oversee most of Day 1. With this many topics, how deep will faculty talks get to go? Buckle up derm buttercups because Day 1 is designed to set the stage for and tone of LVD: broad, organic (not USDA), cutting edge, and practical. While faculty will be hitting the key take homes through fast paced didactics, the real depth comes in with our case based panels and open label extension Q&As. My responsibility as MC is to ensure attendees can smoothly sip, not chug, the extraordinarily comprehensive landscape of dermatology that will no doubt be reviewed throughout the day.

‍

Any topic in particular you are excited to get current on at LVD25? That’s really tough…If I had to pick, punch biopsy to my head, I will cheat and say I can’t wait to hear the cases. Picture multiple grand rounds over a two-day period…no such thing as too much CPC!

‍

One question you hope gets asked this year—so that it can be addressed! “What’s the best way to translate all of this cutting edge science into patient education that is understandable and empowering?” One thing I always try to do when giving a clinical lecture is to share how I talk to the patient about a disease or a medication. I tell all my trainees to pay attention to how we all do it, take the pieces you like, scrap the rest, and come up with script 2.0. I really hope we the faculty are pushed to share our monologues so to speak, as i want to hear it as well!

‍

Dr. Lawrence Eichenfield

Some of the buzzwords that will come up in your Topical Dermatitis Toolbox talk: Steroid withdrawal syndrome; Roflumilast; Tapinarof; Ruxolitinib;Volumetric prescribing

‍

What will attendees gain from your Dermatitis Challenging Cases panel? What constitutes difficult cases these days? Working through decision making on how long to use systemic agents in pediatric patients with atopic dermatitis and considerations in changing dose or medications.  Practical experiences with challenging patients helps to inform our practices for less challenging ones as well.

‍

You intro and oversee much of LVD Day 1 & 2. With this many topics, will faculty talks get to go deep? We design the program to allow our faculty to give their ‘top tips’ and updates in conditions, but then have extended discussions about the topics through case discussions and panel Q and A!  The faculty loves to talk through our issues and takeaways in relation to our patient experiences.

‍

Any topic or faculty member in particular you are excited to have included at LVD25? There are so many new studies on pigmentary disorders, urticaria, infections autoimmune diseases and other ‘hot topics’ it is hard to pick a favorite!

‍

Day 2 Session V: What are some of the “diseases that need to be on the dermatologist’s radar”? Ruth Ann Vleugels has been helping to transform our therapies for our autoimmune conditions, rare but serious diseases that can be managed better. HS care is evolving, and we should know the options.  Do we “lich” lichenoid dermatoses?  Adam Friedman will help us to like to treat them.

‍

What are you hoping attendees gain from Pediatric Dermatology in 2025—is there much new? Emerging oral therapies for pediatric psoriasis- we are ready for a breakthrough!, changing approaches to alopecia areata vitiligo. And new EB drugs!

‍

Dr. Vishal A. Patel

What to gain from your Leveling the Field in Cancerization session? Are we making great strides? Learn evidence-based, patient-centered, and highly effective strategies for addressing the spectrum of field cancerization. This session will highlight approaches ranging from topical treatments, chemical peels, light and laser therapies, to oral medications—showcasing the great strides being made in tailoring treatments to individual patients and, ultimately, preventing cancers from forming in the first place.

You intro and oversee much of LVD Day 3. Anything specific new that you’re looking forward to hearing? Day 3 features our dedicated Cutaneous Malignancies Symposium, showcasing the latest advances across the full spectrum of skin cancer diagnosis and treatment. From staging and workup to breakthrough therapies like neoadjuvant immunotherapy—plus lively debates on controversial topics with internationally recognized experts—this crash course in cutaneous oncology is one you won’t want to miss!

Day 3 Session VII: What’s gonna be hot in The Keratinocyte Carcinoma Talk Show? Join a dynamic discussion with a dermatologist, Mohs surgeon, head and neck surgical oncologist, and medical oncologist as they tackle the full spectrum of keratinocyte carcinoma (KC) management. From staging and therapy selection to the role of adjuvant treatments, this engaging ‘talk show’ format will cover everything you need to know about KC.

Is there a particular debate(s) you are most looking forward to in the Session IX Debates? All of them! Four important topics right now in Cutaneous Oncology! See experts debate on the role of adjuvant radiation and medical therapies, gene expression profiling, and if superficial radiation therapy should be widely used for skin cancers.

‍

Dr. Tina Bhutani

Takeaway that will come up in your talk, A Deeper Look at Plaque Psoriasis: A Systemic Disease that May Require Systemic Treatment: We will review what’s new and exciting in systemic treatment options for psoriasis including recent data and future advances in therapy! 

You intro and oversee much of Day 2. What topic(s) are you most excited to cover? Despite the multitude of treatment options for psoriasis, no option is perfect for every patient. We will examine how best to evaluate and treat your patients, even those with complex histories and unique needs.

Any topic or faculty member in particular you are excited to have included at LVD25? I am very excited to hear about the treatment of hyperpigmentation from Dr. Heather Woolery Lloyd!

What major pearls may you cover in A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation? Dupilumab now has multiple unique indications in dermatology and I am excited to share some of these updates!

One question you hope gets asked this year—so that it can be addressed! What are some other things that we should be screening our psoriasis patients for and how can we address comorbidities?